Children's Allegra Hives Patent Expiration

Children's Allegra Hives is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is protected by 19 US drug patents filed from 2013 to 2015. Out of these, 1 drug patents are active and 18 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 02, 2030. Details of Children's Allegra Hives's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6187791

(Pediatric)

Method of providing an antihistaminic effect in a hepatically impaired patient
Nov, 2012

(11 years ago)

Expired
US6399632

(Pediatric)

Method of providing an antihistaminic effect in a hepatically impaired patient
Nov, 2012

(11 years ago)

Expired
US5578610 Piperidine derivatives
Nov, 2013

(10 years ago)

Expired
US7138524 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
May, 2014

(10 years ago)

Expired
US7135571 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
May, 2014

(10 years ago)

Expired
US5578610

(Pediatric)

Piperidine derivatives
May, 2014

(10 years ago)

Expired
US7138524

(Pediatric)

Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
Nov, 2014

(9 years ago)

Expired
US7135571

(Pediatric)

Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
Nov, 2014

(9 years ago)

Expired
US5738872 Pharmaceutical composition for piperidinoalkanol compounds
Feb, 2015

(9 years ago)

Expired
US5932247 Pharmaceutical composition for piperidinoalkanol compounds
Feb, 2015

(9 years ago)

Expired
US5855912 Pharmaceutical compositions for piperidinalkanol compounds
Feb, 2015

(9 years ago)

Expired
US6113942 Pharmaceutical composition for piperidinoalkanol compounds
Feb, 2015

(9 years ago)

Expired
US5932247

(Pediatric)

Pharmaceutical composition for piperidinoalkanol compounds
Aug, 2015

(8 years ago)

Expired
US5855912

(Pediatric)

Pharmaceutical compositions for piperidinalkanol compounds
Aug, 2015

(8 years ago)

Expired
US6113942

(Pediatric)

Pharmaceutical composition for piperidinoalkanol compounds
Aug, 2015

(8 years ago)

Expired
US6037353 Method of providing an antihistaminic effect in a hepatically impaired patient
Mar, 2017

(7 years ago)

Expired
US6037353

(Pediatric)

Method of providing an antihistaminic effect in a hepatically impaired patient
Sep, 2017

(6 years ago)

Expired
US6723348 Orodispersible tablets containing fexofenadine
Nov, 2021

(2 years ago)

Expired
US8933097 Fexofenadine suspension formulation
Aug, 2030

(6 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Children's Allegra Hives is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Children's Allegra Hives's family patents as well as insights into ongoing legal events on those patents.

Children's Allegra Hives's family patents

Children's Allegra Hives has patent protection in a total of 38 countries. It's US patent count contributes only to 7.5% of its total global patent coverage. 13 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Children's Allegra Hives.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Children's Allegra Hives's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 02, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Children's Allegra Hives Generics:

There are no approved generic versions for Children's Allegra Hives as of now.

How can I launch a generic of Children's Allegra Hives before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Children's Allegra Hives's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Children's Allegra Hives's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Children's Allegra Hives -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
30 mg/5 mL 25 Jan, 2010 1 18 Nov, 2014 14 Mar, 2017 Eligible
30 mg, 60 mg and 180 mg




About Children's Allegra Hives

Children'S Allegra Hives is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is used for treating respiratory allergies, hives (urticaria), and their associated symptoms in adults and children. Children'S Allegra Hives uses Fexofenadine Hydrochloride as an active ingredient. Children'S Allegra Hives was launched by Chattem Sanofi in 2011.

Market Authorisation Date:

Children's Allegra Hives was approved by FDA for market use on 24 January, 2011.

Active Ingredient:

Children's Allegra Hives uses Fexofenadine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Fexofenadine Hydrochloride ingredient

Treatment:

Children's Allegra Hives is used for treating respiratory allergies, hives (urticaria), and their associated symptoms in adults and children.

Dosage:

Children's Allegra Hives is available in the following dosage forms - suspension form for oral use, tablet, orally disintegrating form for oral use, tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
30MG TABLET Discontinued ORAL
30MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** SUSPENSION Discontinued ORAL
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET, ORALLY DISINTEGRATING Discontinued ORAL